GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

We determined the molecular mechanisms by which the novel therapeutic GZ17-6.02 killed non-small cell lung cancer (NSCLC) cells. Erlotinib, afatinib, and osimertinib interacted with GZ17-6.02 to kill NSCLC cells expressing mutant EGFR proteins. GZ17-6.02 did not interact with any EGFR inhibitor to k...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, West, Cameron, Moore, Robert P., Von Hoff, Daniel, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417372/
https://www.ncbi.nlm.nih.gov/pubmed/34490108
http://dx.doi.org/10.3389/fonc.2021.711043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417372/
https://www.ncbi.nlm.nih.gov/pubmed/34490108
http://dx.doi.org/10.3389/fonc.2021.711043

Ejemplares similares